Industry News

TAKE Solutions Ltd., a global business technology solutions provider, was awarded a patent by the United States Patent and Trademark Office (USPTO) for its "Method for Optimizing Clinical Data Standardization". It provides cost-effective and comprehensive solutions for enterprises across diverse sectors including pharmaceuticals, high technology, consumer packaged goods. TAKE’s global headquarters is in Chennai, India; its US headquarters is located in Princeton, New Jersey. This process leverages TAKE Solutions’ clinical accelerators to reduce the time taken to standardize trial data by over 50% (when compared to standardization without the accelerators), thus reducing time to market.

[adsense:336x280:8701650588]

Maruishi Pharmaceutical Co., Ltd.  & Daiichi Sankyo Company, Limited, a global pharmaceutical company Collaborate to commercialize the general anaesthesia analgesic, remifentanil injection generic. Maruishi Pharmaceutical is currently applying for a manufacture and marketing license. Once Maruishi Pharmaceutical has acquired a license for the manufacturing and marketing of this drug, the plan is for Maruishi Pharmaceutical to handle its manufacture and Daiichi Sankyo to handle its marketing, while both companies will jointly conduct promotion activities.

Zydus Cadila, a global pharmaceutical company, has received the final approval from the US Food and Drug Administration (FDA) to market pyridostigmine bromide tablets USP, 60 mg.  It is used for treating various neurological disorders.

Wockhardt has received final approval from the US FDA for marketing 5mg/5ml of oxycodone HCI liquid. The company is launching the product soon and will be amongst the few generic versions of this product in the market.

Aurobindo Pharma got final approvals from the US FDA of azithromycin for injection USP, 500mg /vial and entacapone tablets. Azithromycin for injection USP, 500mg/vial is bioequivalent and therapeutically equivalent to the reference listed drug product (RLD) Zithromax (azithromycin for injection) 500mg/vial of Pfizer, Inc. Azithromycin for injection, USP is a macrolide antibacterial drug indicated for the treatment of patients with infections caused by susceptible strains of the designated microorganisms in the conditions such as community-acquired pneumonia and pelvic inflammatory disease.

Shri B P Sharma, Secretary Health, Ministry of Health & Family Welfare and Chairman, Indian Pharmacopoeia Commission, Government of India launched an Android Mobile Applications for Adverse Drug Reactions (ADRs) reporting facility to the stakeholders of Pharmacovigilance Programme of India (PvPI). The mobile application for ADR reporting was specifically designed to facilitate the needs of the IPC, to ensure hassle free ADR reporting for the stakeholders. The mobile application is expected to provide a platform for the private healthcare professionals to report ADRs to safeguard and enhance public health by ensuring the safety, efficacy and quality of drugs.

(NewsVoir); Aggressively moving towards its expansion plans, 1mg.com - India’s leading m-health platform that has also been operating the largest e-Pharmacy marketplace in the country, announced today that it has decided to expand the scope of its platform and is entering the alternate medicine space (AYUSH categories) through the acquisition of www. Homeobuy.com. Homeobuy is a web platform for homeopathy medicines. With this acquisition, 1mg will re-brand the website to www. 1mgAyush.com and make Homeopathic & Ayurvedic medicines available to customers in New Delhi.

[adsense:336x280:8701650588]

Sandoz, a Novartis company, has launched Glatopa in US markets. Glatopa is the first generic version of Teva's Copaxone (glatiramer acetate injection) 20 mg/ml one-time-daily multiple sclerosis therapy. It is used in treatment of Multiple Sclerosis (MS).

Intas Pharmaceuticals on Friday announced launching of Razumab, a biosimilar to Lucentis (ranibizumab). Novartis' eye drug Lucentis has long had a target on its back from biosimilar makers who would love to get some piece of the $4 billion in annual sales it racks up.  Razumab will be 25 per cent cheaper than its imported alternate.